A Multi-Center Randomized Double-blind Placebo-controlled Dose-finding Study to Evaluate the Safety Tolerability Pharmacokinetics and Pharmacodynamics of CK-3773274 in Adults with Symptomatic Hypertrophic Cardiomyopathy
Are you eligible to participate in this study?
You may be eligible for this study if you meet the following criteria:
-
Conditions: Hypertrophic Cardiomyopathy
-
Age: Between 18 years - 70 years
-
Gender: Male or Female
-
Other Inclusion Criteria:
- Males and females between 18 and 85 years of age at screening
- Body weight is > = 45 kg at screening
- Diagnosed with HCM
- Participants on beta-blockers, verapamil, diltiazem, or ranolazine should have been on stable doses for >4 weeks prior to randomization and anticipate remaining on the same medication regimen during the study
- For Cohort 3: Participants must be taking disopyramide. Patients should have been on stable disopyramide doses for >4 weeks prior to screening and anticipate remaining on the same medication regimen during the study
You may not be eligible for this study if the following are true:
-
- Aortic stenosis or fixed subaortic obstruction
- Known infiltrative or storage disorder causing cardiac hypertrophy that mimics HCM
- History of LV systolic dysfunction
- Documented history of current obstructive coronary artery disease (>70% stenosis in one or more epicardial coronary arteries) or documented history of myocardial infarction.
- Has been treated with septal reduction therapy (surgical myectomy or percutaneous alcohol septal ablation) or has plans for either treatment during the study period (
- For Cohorts 1, 2 and 4: Has been treated with disopyramide or antiarrhythmic drugs that have negative inotropic activity within 4 weeks prior to screening
- Paroxysmal atrial fibrillation or flutter documented during the screening period
- Paroxysmal or permanent atrial fibrillation requiring rhythm restoring treatment (eg, direct-current cardioversion, ablation procedure, or antiarrhythmic therapy) = < 6 months prior to screening
- History of syncope or sustained ventricular tachyarrhythmia with exercise within 6 months prior to screening
- Has received prior treatment with CK-3773274 or is currently receiving mavacamten
- For Cohort 4: has any documented history of LVOT-G > = 30 mmHg at rest, with Valsalva, or with exercise
If you are registered as a volunteer, please log in to contact the study team/express interest in this study.